Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a
disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide …

Hepatitis B virus (HBV) specifically infects hepatocytes and causes severe liver diseases.
The HBV life cycle is unique in that the genomic DNA (relaxed-circular partially double …

Representatives from academia, industry, regulatory agencies, and patient groups
convened in March 2019 with the primary goal of developing agreement on chronic hepatitis …

Current antiviral therapies, such as pegylated interferon-α and nucleos (t) ide analogues,
effectively improve the quality of life of patients with chronic hepatitis B. However, they can …

Background The current outbreak of pandemic coronavirus disease 2019 (COVID-19)
aggravates serious need for effective therapeutics. Over recent years, drug repurposing has …

With 296 million cases estimated worldwide, chronic hepatitis B virus (HBV) infection is the
most common risk factor for hepatocellular carcinoma (HCC). HBV-encoded oncogene X …

The hepatitis B virus (HBV) counts as a major global health problem, as it presents a
significant causative factor for liver-related morbidity and mortality. The development of …

Cryptosporidium infects gastrointestinal epithelium and is a leading cause of infectious
diarrhea and diarrheal-related death in children worldwide. There are no vaccines and no …

Direct‐acting antiviral agents (DAAs) represent a class of drugs targeting viral proteins and
have been demonstrated to be very successful in combating viral infections in clinic …

Current treatments against chronic hepatitis B (CHB) include pegylated interferon alpha
(Peg‐IFNα) and nucleos (t) ide analogs (NAs), the latter targeting the viral retrotranscriptase …